APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liposomal and Lipid-based Nanoparticle Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Liposomal and Lipid-based Nanoparticle Drug Industry Growth and Trends Forecast to 2032

2 January 2026121 pages

Choose your research edition.

Industry ResearchLiposomal and Lipid-based Nanoparticle Drug Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposomal and Lipid-based Nanoparticle Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Liposomal and Lipid-based Nanoparticle Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposomal and Lipid-based Nanoparticle Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposomal and Lipid-based Nanoparticle Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

According to APO Research, the global Liposomal and Lipid-based Nanoparticle Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liposomal and Lipid-based Nanoparticle Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Liposomal and Lipid-based Nanoparticle Drug market include Acrotech Biopharma, Alnylam, Bausch Health, Chiesi Farmaceutici, CSPC, Fudan-Zhangjiang, Gilead Sciences, Ipsen and Jazz, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Liposomal and Lipid-based Nanoparticle Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Liposomal and Lipid-based Nanoparticle Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Liposomal and Lipid-based Nanoparticle Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Liposomal and Lipid-based Nanoparticle Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Liposomal and Lipid-based Nanoparticle Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Liposomal and Lipid-based Nanoparticle Drug Market by Company

Acrotech Biopharma

Alnylam

Bausch Health

Chiesi Farmaceutici

CSPC

Fudan-Zhangjiang

Gilead Sciences

Ipsen

Jazz

Kinyond

Leadiant Biosciences

Luye Pharma

Pacira

Sayre Therapeutics

TTY Biopharma

Zydus Cadila

Johnson & Johnson

Sun Pharmaceutical

Teva

Takeda

Liposomal and Lipid-based Nanoparticle Drug Segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Liposomal and Lipid-based Nanoparticle Drug Segment by Application

Hospital

Retail Pharmacy

Other

Liposomal and Lipid-based Nanoparticle Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid-based Nanoparticle Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid-based Nanoparticle Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid-based Nanoparticle Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Liposomal and Lipid-based Nanoparticle Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2021-2026) Table 4. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2027-2032) Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2026) Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2026) Table 24. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Liposomal and Lipid-based Nanoparticle Drug Industry Trends Table 37. Liposomal and Lipid-based Nanoparticle Drug Industry Drivers Table 38. Liposomal and Lipid-based Nanoparticle Drug Industry Opportunities and Challenges Table 39. Liposomal and Lipid-based Nanoparticle Drug Industry Restraints Table 40. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Company (2021-2026) Table 42. Global Liposomal and Lipid-based Nanoparticle Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Liposomal and Lipid-based Nanoparticle Drug Key Company Headquarters & Area Served Table 44. Global Liposomal and Lipid-based Nanoparticle Drug Company, Product Type & Application Table 45. Global Liposomal and Lipid-based Nanoparticle Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Liposomal and Lipid-based Nanoparticle Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Acrotech Biopharma Company Information Table 49. Acrotech Biopharma Business Overview Table 50. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 52. Acrotech Biopharma Recent Development Table 53. Alnylam Company Information Table 54. Alnylam Business Overview Table 55. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 57. Alnylam Recent Development Table 58. Bausch Health Company Information Table 59. Bausch Health Business Overview Table 60. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 62. Bausch Health Recent Development Table 63. Chiesi Farmaceutici Company Information Table 64. Chiesi Farmaceutici Business Overview Table 65. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 67. Chiesi Farmaceutici Recent Development Table 68. CSPC Company Information Table 69. CSPC Business Overview Table 70. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 72. CSPC Recent Development Table 73. Fudan-Zhangjiang Company Information Table 74. Fudan-Zhangjiang Business Overview Table 75. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 77. Fudan-Zhangjiang Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. Ipsen Company Information Table 84. Ipsen Business Overview Table 85. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 87. Ipsen Recent Development Table 88. Jazz Company Information Table 89. Jazz Business Overview Table 90. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 92. Jazz Recent Development Table 93. Kinyond Company Information Table 94. Kinyond Business Overview Table 95. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 97. Kinyond Recent Development Table 98. Leadiant Biosciences Company Information Table 99. Leadiant Biosciences Business Overview Table 100. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 102. Leadiant Biosciences Recent Development Table 103. Luye Pharma Company Information Table 104. Luye Pharma Business Overview Table 105. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 107. Luye Pharma Recent Development Table 108. Pacira Company Information Table 109. Pacira Business Overview Table 110. Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 112. Pacira Recent Development Table 113. Sayre Therapeutics Company Information Table 114. Sayre Therapeutics Business Overview Table 115. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 117. Sayre Therapeutics Recent Development Table 118. TTY Biopharma Company Information Table 119. TTY Biopharma Business Overview Table 120. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 122. TTY Biopharma Recent Development Table 123. Zydus Cadila Company Information Table 124. Zydus Cadila Business Overview Table 125. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 127. Zydus Cadila Recent Development Table 128. Johnson & Johnson Company Information Table 129. Johnson & Johnson Business Overview Table 130. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 132. Johnson & Johnson Recent Development Table 133. Sun Pharmaceutical Company Information Table 134. Sun Pharmaceutical Business Overview Table 135. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 137. Sun Pharmaceutical Recent Development Table 138. Teva Company Information Table 139. Teva Business Overview Table 140. Teva Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 142. Teva Recent Development Table 143. Takeda Company Information Table 144. Takeda Business Overview Table 145. Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio Table 147. Takeda Recent Development Table 148. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2026) Table 151. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Liposomal and Lipid-based Nanoparticle Drug Market Share Forecast by Country (2027-2032) Table 153. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2026) Table 156. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2026) Table 161. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share Forecast by Country (2027-2032) Table 163. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2026) Table 166. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2026) Table 171. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Liposomal and Lipid-based Nanoparticle Drug Product Image Figure 3. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2021-2032) Figure 7. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Liposomes Drugs Image Figure 13. Global Liposomes Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Lipid Nanoparticle Drugs Image Figure 15. Global Lipid Nanoparticle Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Type 2025 VS 2032 Figure 18. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2032) Figure 19. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2032) Figure 21. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Retail Pharmacy Image Figure 26. Global Retail Pharmacy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Other Image Figure 28. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application 2025 VS 2032 Figure 31. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2032) Figure 32. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2032) Figure 34. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Liposomal and Lipid-based Nanoparticle Drug Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032) Figure 41. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032) Figure 44. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032) Figure 47. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032) Figure 50. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomes Drugs
  • Lipid Nanoparticle Drugs
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Acrotech Biopharma
  • Alnylam
  • Bausch Health
  • Chiesi Farmaceutici
  • CSPC
  • Fudan-Zhangjiang
  • Gilead Sciences
  • Ipsen
  • Jazz
  • Kinyond
  • Leadiant Biosciences
  • Luye Pharma
  • Pacira
  • Sayre Therapeutics
  • TTY Biopharma
  • Zydus Cadila
  • Johnson & Johnson
  • Sun Pharmaceutical
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
  8. 1.5.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (2021-2032)
2 Liposomal and Lipid-based Nanoparticle Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Liposomes Drugs
  3. 2.1.2 Lipid Nanoparticle Drugs
  4. 2.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
  5. 2.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions
  9. 2.3.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Type (2021-2026)
3 Liposomal and Lipid-based Nanoparticle Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Retail Pharmacy
  4. 3.1.3 Other
  5. 3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
  6. 3.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions
  10. 3.3.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
  2. 4.2 Liposomal and Lipid-based Nanoparticle Drug Industry Drivers
  3. 4.3 Liposomal and Lipid-based Nanoparticle Drug Industry Opportunities and Challenges
  4. 4.4 Liposomal and Lipid-based Nanoparticle Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Liposomal and Lipid-based Nanoparticle Drug Revenue (2021-2026)
  2. 5.2 Global Liposomal and Lipid-based Nanoparticle Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Liposomal and Lipid-based Nanoparticle Drug Key Company Headquarters & Area Served
  4. 5.4 Global Liposomal and Lipid-based Nanoparticle Drug Company, Product Type & Application
  5. 5.5 Global Liposomal and Lipid-based Nanoparticle Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Liposomal and Lipid-based Nanoparticle Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Liposomal and Lipid-based Nanoparticle Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Liposomal and Lipid-based Nanoparticle Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Acrotech Biopharma
  2. 6.1.1 Acrotech Biopharma Company Information
  3. 6.1.2 Acrotech Biopharma Business Overview
  4. 6.1.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  6. 6.1.5 Acrotech Biopharma Recent Developments
  7. 6.2 Alnylam
  8. 6.2.1 Alnylam Company Information
  9. 6.2.2 Alnylam Business Overview
  10. 6.2.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  12. 6.2.5 Alnylam Recent Developments
  13. 6.3 Bausch Health
  14. 6.3.1 Bausch Health Company Information
  15. 6.3.2 Bausch Health Business Overview
  16. 6.3.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  18. 6.3.5 Bausch Health Recent Developments
  19. 6.4 Chiesi Farmaceutici
  20. 6.4.1 Chiesi Farmaceutici Company Information
  21. 6.4.2 Chiesi Farmaceutici Business Overview
  22. 6.4.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  24. 6.4.5 Chiesi Farmaceutici Recent Developments
  25. 6.5 CSPC
  26. 6.5.1 CSPC Company Information
  27. 6.5.2 CSPC Business Overview
  28. 6.5.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  30. 6.5.5 CSPC Recent Developments
  31. 6.6 Fudan-Zhangjiang
  32. 6.6.1 Fudan-Zhangjiang Company Information
  33. 6.6.2 Fudan-Zhangjiang Business Overview
  34. 6.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  36. 6.6.5 Fudan-Zhangjiang Recent Developments
  37. 6.7 Gilead Sciences
  38. 6.7.1 Gilead Sciences Company Information
  39. 6.7.2 Gilead Sciences Business Overview
  40. 6.7.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  42. 6.7.5 Gilead Sciences Recent Developments
  43. 6.8 Ipsen
  44. 6.8.1 Ipsen Company Information
  45. 6.8.2 Ipsen Business Overview
  46. 6.8.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  48. 6.8.5 Ipsen Recent Developments
  49. 6.9 Jazz
  50. 6.9.1 Jazz Company Information
  51. 6.9.2 Jazz Business Overview
  52. 6.9.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  54. 6.9.5 Jazz Recent Developments
  55. 6.10 Kinyond
  56. 6.10.1 Kinyond Company Information
  57. 6.10.2 Kinyond Business Overview
  58. 6.10.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  60. 6.10.5 Kinyond Recent Developments
  61. 6.11 Leadiant Biosciences
  62. 6.11.1 Leadiant Biosciences Company Information
  63. 6.11.2 Leadiant Biosciences Business Overview
  64. 6.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  66. 6.11.5 Leadiant Biosciences Recent Developments
  67. 6.12 Luye Pharma
  68. 6.12.1 Luye Pharma Company Information
  69. 6.12.2 Luye Pharma Business Overview
  70. 6.12.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  72. 6.12.5 Luye Pharma Recent Developments
  73. 6.13 Pacira
  74. 6.13.1 Pacira Company Information
  75. 6.13.2 Pacira Business Overview
  76. 6.13.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  78. 6.13.5 Pacira Recent Developments
  79. 6.14 Sayre Therapeutics
  80. 6.14.1 Sayre Therapeutics Company Information
  81. 6.14.2 Sayre Therapeutics Business Overview
  82. 6.14.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  84. 6.14.5 Sayre Therapeutics Recent Developments
  85. 6.15 TTY Biopharma
  86. 6.15.1 TTY Biopharma Company Information
  87. 6.15.2 TTY Biopharma Business Overview
  88. 6.15.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  90. 6.15.5 TTY Biopharma Recent Developments
  91. 6.16 Zydus Cadila
  92. 6.16.1 Zydus Cadila Company Information
  93. 6.16.2 Zydus Cadila Business Overview
  94. 6.16.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  96. 6.16.5 Zydus Cadila Recent Developments
  97. 6.17 Johnson & Johnson
  98. 6.17.1 Johnson & Johnson Company Information
  99. 6.17.2 Johnson & Johnson Business Overview
  100. 6.17.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  102. 6.17.5 Johnson & Johnson Recent Developments
  103. 6.18 Sun Pharmaceutical
  104. 6.18.1 Sun Pharmaceutical Company Information
  105. 6.18.2 Sun Pharmaceutical Business Overview
  106. 6.18.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  108. 6.18.5 Sun Pharmaceutical Recent Developments
  109. 6.19 Teva
  110. 6.19.1 Teva Company Information
  111. 6.19.2 Teva Business Overview
  112. 6.19.3 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  114. 6.19.5 Teva Recent Developments
  115. 6.20 Takeda
  116. 6.20.1 Takeda Company Information
  117. 6.20.2 Takeda Business Overview
  118. 6.20.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
  120. 6.20.5 Takeda Recent Developments
7 North America
  1. 7.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
  3. 7.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
  3. 10.3 South America Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst